https://clinlabint.com/wp-content/uploads/sites/2/2021/01/3_AD_SHIMADZU.jpg137910003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Experience New Benchmarks
One syndromic panel that tests everything but your patience.
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/1_AD_BIO-FIRE.jpg137910003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00How the test was one.
As COVID-19 continues to impact countries worldwide, accurate screening is needed to establish serological status of different populations. Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay, for the detection of total anti-nucleocapsid antibodies (IgM, IgA, IgG) to SARS-CoV-2. In one test, the assay helps identify the immune response to coronavirus SARS-CoV-2, the virus associated with COVID-19.
https://info.bio-rad.com/cdg-sars-cov-2-ous?WT.mc_id=200814028804 Read more
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00COVID-19 Serology Testing for IVD
ender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, has launched ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus which causes COVID-19. US FDA clearance is anticipated in September this year.
ender MASS is highly specific, easy-to-use and fast – providing results from a simple nasopharyngeal swab in 30 minutes. It is designed to enable rapid diagnosis for critical settings including schools, manufacturing facilities, travel, hospitals and care homes, as well as enabling centralized laboratories to accelerate and increase throughput.
ender diagnostics specializes in isothermal PCR-based test kits for laboratory and on-site diagnosis. It launched the ender LAB test in June 2020, which enables laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes, significantly faster than currently available PCR tests, which take several hours.
The newly approved ender MASS offers further benefits by enabling detection in a simplified and accelerated process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations such as airports and cruise ships. The simplified workflows and analysis mean laboratories can process up to eight times as many tests compared to conventional PCR testing over the same period.
The company is also moving ahead with development of a mobile point-of-care test for acute COVID-19 cases, called ender MOBILE. Launch in Europe is planned during Autumn this year.
For more information, visit: https://enderdiagnostics.com
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/SARS-CoV__1_.jpg100012803wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00ender diagnostics launches second CE-certified COVID-19 rapid test
The Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.
For more information, visit: thenativeantigencompany.com/influenza-services-landing-page
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/flu_virus__1_.jpg116211523wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00The Native Antigen Company introduces custom contract service for influenza researchers
Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.
For more information, visit: https://absoluteantibody.com/general/sars-cov-2-neutralizing-antibodies
Thermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.
For more information, visit: www.thermofisher.com/smartvuepro
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/Thermo_Scientific_Smart-Vue__1_-scaled.jpg256014623wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring
Abingdon Health has received the CE mark for its COVID-19 antibody test, called AbC-19TM Rapid Test. The test is now approved for professional use in the UK and EU.
The test uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a lab.
The test will now be mass produced with roll out expected from the end of August. The company says it will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
AbC-19 Rapid Test detects IgG antibodies to the SARS-CoV-2 virus with 99.4% accuracy according to the company. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
Chris Yates, Abingdon Health CEO, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
Abingdon Health is a UK-based medical device manufacturer. To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-Rapid Test Consortium (UK-RTC) in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per month.
The tests will also undergo ease of use trials with the general public to allow the Medical and Healthcare products Regulatory Agency to provide the necessary approvals for it to be used by the public as a home test which is expected in the coming months. These trials will be performed in conjunction with the Ulster University, using around 2000 volunteers.
For more information, visit: www.abingdonhealth.com
https://clinlabint.com/wp-content/uploads/sites/2/2021/01/abingdon_health.jpg91012863wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Abingdon Health receives CE mark for COVID-19 antibody rapid test
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
SmartLab Respiratory Analysis
, /in Featured Articles /by 3wmediaExperience New Benchmarks
, /in Featured Articles /by 3wmediaBasic Metabolic Panel. STAT.
, /in Featured Articles /by 3wmediaHow the test was one.
, /in Featured Articles /by 3wmediaOne syndromic panel that tests everything but your patience.
COVID-19 Serology Testing for IVD
, /in Product News /by 3wmediaAs COVID-19 continues to impact countries worldwide, accurate screening is needed to establish serological status of different populations. Bio-Rad now offers the Platelia SARS-CoV-2 Total Ab assay, for the detection of total anti-nucleocapsid antibodies (IgM, IgA, IgG) to SARS-CoV-2. In one test, the assay helps identify the immune response to coronavirus SARS-CoV-2, the virus associated with COVID-19.
https://info.bio-rad.com/cdg-sars-cov-2-ous?WT.mc_id=200814028804
Read more
ender diagnostics launches second CE-certified COVID-19 rapid test
, /in Product News /by 3wmediaender diagnostics, a Swiss company specializing in the development of rapid molecular biological tests, has launched ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus which causes COVID-19. US FDA clearance is anticipated in September this year.
ender MASS is highly specific, easy-to-use and fast – providing results from a simple nasopharyngeal swab in 30 minutes. It is designed to enable rapid diagnosis for critical settings including schools, manufacturing facilities, travel, hospitals and care homes, as well as enabling centralized laboratories to accelerate and increase throughput.
ender diagnostics specializes in isothermal PCR-based test kits for laboratory and on-site diagnosis. It launched the ender LAB test in June 2020, which enables laboratories to directly detect SARS-CoV-2 on standard real-time PCR devices within 30 minutes, significantly faster than currently available PCR tests, which take several hours.
The newly approved ender MASS offers further benefits by enabling detection in a simplified and accelerated process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations such as airports and cruise ships. The simplified workflows and analysis mean laboratories can process up to eight times as many tests compared to conventional PCR testing over the same period.
The company is also moving ahead with development of a mobile point-of-care test for acute COVID-19 cases, called ender MOBILE. Launch in Europe is planned during Autumn this year.
Read more
The Native Antigen Company introduces custom contract service for influenza researchers
, /in Product News /by 3wmediaThe Native Antigen Company (now part of LGC’s Clinical Diagnostics Division), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has introduced its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.
The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins.
The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.
Read more
Absolute Antibody offers researchers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients
, /in Product News /by 3wmediaAbsolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalogue.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent study to display neutralizing activity against SARS-CoV-2. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of species, isotypes and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers the SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. In addition, the antibodies are available in species such as mouse and rabbit for detection applications and co-labelling studies; fragment formats for better tissue penetration and in vivo imaging; and with engineered Fc Silent domains to facilitate research into antibody-dependent enhancement. All antibodies are recombinantly produced for ensured batch-to-batch reproducibility, high purity and low endotoxin levels.
The new neutralizing antibodies join Absolute Antibody’s full collection of engineered coronavirus reagents, including the spike glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in diagnostic tests.
Absolute Antibody is also supporting coronavirus research by providing antibody engineering and manufacturing services, including the production of gram quantities of human antibodies sequenced from recovering COVID-19 patients.
Read more
Thermo Fisher launches Smart-Vue Pro to ensure sample protection with remote monitoring
, /in Product News /by 3wmediaThermo Fisher Scientific has launched the Thermo Scientific Smart-Vue Pro, a next-generation remote monitoring solution for biotechnology, pharmaceutical, clinical and academic laboratories. The device is designed to enable superior levels of sample protection, workflow efficiencies, asset/cost optimization and regulatory compliance.
With the option for an on-premise or cloud setup, the Thermo Scientific Smart-Vue Pro Remote Monitoring Solution provides real-time, continuous monitoring of critical laboratory equipment parameters and immediately notifies users about off-limit measurements that, if left unattended, could compromise sample safety and integrity. Notifications are delivered by email, text message or phone call, through a secure network, prompting corrective action.
Importantly, the Smart-Vue Pro solution delivers fully traceable data logging and secure user-level access to the complete system functionality at anytime from anywhere with Internet access, facilitating compliance with a wide range of regulatory standards, including 21CFR Part 11 and cGxP.
Operating on the LoRaWAN (Long-Range Wide Area Network) technology, the Smart-Vue Pro solution can simultaneously monitor conditions across several laboratories located on different floors or buildings. The LoRaWAN technology ensures a single receiver can cover up to 2km line of sight in urban areas, eliminating the need to invest in multiple monitoring systems. Scalability is further enhanced through the advanced modular, customizable architecture of the Smart-Vue Pro solution that supports up to four pre-calibrated Smart Digital Sensors. As a result, the system can monitor many pieces of equipment or multiple parameters within one piece of equipment at the same time. Finally, the Smart-Vue Pro solution allows for easy expansion to accommodate additional pieces of equipment without the need for costly upgrades. Overall, this improved scalability results in considerable installation, hardware and maintenance cost savings.
The Smart-Vue Pro solution features an interactive, colour touchscreen that displays data along with visual and audio alarms for at-a-glance monitoring, while enabling simplified and customizable views for an enhanced user experience.
Thermo Fisher Scientific supports the Smart-Vue Pro solution with end-to-end service and support packages to guide users through installation, validation, implementation and maintenance.
The Smart-Vue Pro solution is capable of monitoring temperatures ranging from −200°C to +150°C, relative humidity and dry contact state, with CO2 concentration and differential pressure set to be added to the system’s measurement capabilities in the near future.
Read more
Abingdon Health receives CE mark for COVID-19 antibody rapid test
, /in Product News /by 3wmediaAbingdon Health has received the CE mark for its COVID-19 antibody test, called AbC-19TM Rapid Test. The test is now approved for professional use in the UK and EU.
The test uses a small drop of blood from a finger-prick and shows results in 20 minutes, without the need to send a sample to a lab.
The test will now be mass produced with roll out expected from the end of August. The company says it will produce 500,000 COVID-19 antibody tests a month from October and one million a month from January 2021.
AbC-19 Rapid Test detects IgG antibodies to the SARS-CoV-2 virus with 99.4% accuracy according to the company. Testing was performed at the Ulster University and at the laboratories of Abingdon Health.
Chris Yates, Abingdon Health CEO, said: “This UK designed, developed and manufactured high-quality rapid diagnostic test is a breakthrough for UK life sciences and a triumph of British business.
“It has been a company-wide effort at Abingdon Health to achieve this milestone in such a short space of time. Our research and development teams have been working two shifts a day, seven days a week, to develop the test. We have deployed nearly fifteen times the number of people that would be on a typical project to deliver this test as quickly as possible.”
Abingdon Health is a UK-based medical device manufacturer. To develop and mass produce the volumes needed for the UK population, Abingdon Health set up and led the UK-Rapid Test Consortium (UK-RTC) in April this year. The consortium brings together the UK’s largest rapid test medical manufacturers, working together to provide capacity for delivery of more than a million tests per month.
The tests will also undergo ease of use trials with the general public to allow the Medical and Healthcare products Regulatory Agency to provide the necessary approvals for it to be used by the public as a home test which is expected in the coming months. These trials will be performed in conjunction with the Ulster University, using around 2000 volunteers.
Read more